Asia-Pacific Western Blotting Market Forecast Analysis 2024-2032
As per Triton’s research report, the western blotting market in the Asia-Pacific is estimated to expand in terms of revenue at a CAGR of 6.68% during the forecast period 2024-2032.
As per UNAIDS, an estimated 6.7 million people in Asia and the Pacific are living with HIV as of 2023. The growing prevalence of HIV and Hepatitis B in this region, coupled with underdiagnosis due to a lack of clear diagnostic criteria and treatment guidelines, is expected to drive demand for more reliable and accurate diagnostic methods. Western blotting, a widely recognized technique for confirming the presence of viral infections like HIV and Hepatitis B, will likely see increased usage as healthcare providers aim to improve detection rates. As more people are tested and diagnosed, the need for confirmatory tests like western blotting will rise, contributing to market growth in the region.
The countries analyzed in this region include China, Australia & New Zealand, ASEAN Countries, Japan, South Korea, India, and Rest of Asia-Pacific.
China leads with a major market share, recording nearly $53.67 million in 2023.
- In recent years, the number of people living with HIV in China has exceeded 1.05 million, with high-risk groups such as people who inject drugs remaining the most affected.
- The rise in HIV cases, particularly among high-risk groups and younger populations in the country, has led to a growing demand for accurate and reliable diagnostic methods with an added reliance on confirmatory testing methods like western blotting.
- This technique is also utilized in research settings to understand the nature of HIV, develop new treatment methods, and monitor patients’ responses to antiretroviral therapies.
- China’s commitment to funding its HIV response from domestic sources supports investments in diagnostic technologies, contributing to the growth of the western blotting market.
Western Blotting Market Forecast for Japan
The growth of the western blotting market in Japan is influenced by various factors, including the increasing prevalence of chronic diseases, government support for biomedical and biotechnology industries, and expanding research activities in molecular biology, proteomics, and drug discovery. Japan, along with other countries in the Asia-Pacific region, is witnessing a surge in the adoption of western blotting techniques due to growing investment in the pharmaceutical and biotechnology sectors, supported by government funding and initiatives.
The western blotting market is segmented by product, application, and end-user. Based on application, it is further classified into disease diagnostics, agriculture, biomedical & biochemical research, and other applications. The western blotting techniques find its application in the disease diagnostics segment for detecting HIV, autoimmune disorders, and cancer. Technological advancements, rising chronic disease prevalence, and the adoption of multiplexing technologies drive its demand in clinical laboratories.
Contender Analysis in the Western Blotting Market:
Thermo Fisher Scientific Inc is a leading manufacturer of scientific instruments, chemicals, and consumables. The company provides a range of products and services, including analytical instruments, laboratory equipment, software, reagents, and consumables, to industries such as pharmaceuticals, hospitals, biotech, research institutions, and government agencies. Its Specialty Diagnostics segment focuses on delivering immunodiagnostic reagent kits, blood-test systems for diagnosing allergies, asthma, and autoimmune diseases, as well as products for cancer research and medical diagnostics. It is headquartered in Massachusetts, US.
In August 2024, The FDA approved Thermo Fisher Scientific’s SeCore HLA Typing Kit for use as a companion diagnostic with a T-cell receptor therapy to treat synovial sarcoma.
Other key contenders in the market include Io-Techne Corporation, Cell Signaling Technology Inc, Li-Cor Inc, Advansta Inc, and Lumigen Inc.